Self-report Data As a Tool for Subtype Identification in Genetically-defined Parkinson's Disease

Overview

Journal Sci Rep

Specialty Science

Date 2018 Aug 30

PMID 30154511

Citations 8

Authors

Ashley R Winslow

Craig L Hyde

Jemma B Wilk

Nicholas Eriksson

Paul Cannon

Melissa R Miller

Warren D Hirst

Affiliations

Soon will be listed here.

Abstract

Through a targeted recruitment 23andMe has collected DNA and patient-reported symptoms from more than 10,000 subjects reporting a physician-verified diagnosis of PD. This study evaluated the potential of self-report, web-based questionnaires to rapidly assess disease natural history and symptomology in genetically-defined PD populations. While average age-at-diagnosis was significantly lower in GBA mutation carriers compared to idiopathic PD, or iPD (idiopathic PD, defined as no GBA mutations and no LRRK2 G2019S mutation), there were no significant differences in symptoms. Conversely, LRRK2 G2019S carrier status significantly associated with reporting of milder daily symptoms of lightheadedness and several differences were observed at a false discovery rate < 0.1, including increased reporting of changes in walking as an initial symptom of disease, decreased reporting of lightheadedness upon standing, and milder symptoms related to daily functioning. The subclinical differences in symptoms reported by LRRK2 G2019S carriers suggest differences in underlying pathophysiology and/or disease progression in LRRK2 carriers compared to iPD. Importantly, we confirm previous findings in PD genetic subsets where disease characteristics were ascertained through clinical exam. Overall, these data support the effective use of self-report and genetic data to rapidly analyze information from a large disease population or difficult to identify genetic subgroups.

Citing Articles

Fox Insight at 5 years - a cohort of 54,000 participants contributing longitudinal patient-reported outcome, genetic, and microbiome data relating to Parkinson's disease.

Gottesman J, Karim Y, Forbes J, Kirsch L, Stagman K, Korell M Sci Data. 2024; 11(1):615.

PMID: 38866856 PMC: 11169221. DOI: 10.1038/s41597-024-03407-9.

Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.

Kmiecik M, Micheletti S, Coker D, Heilbron K, Shi J, Stagaman K Brain. 2024; 147(6):1996-2008.

PMID: 38804604 PMC: 11146432. DOI: 10.1093/brain/awae073.

Remote assessment of cognition in Parkinson's disease and Cerebellar Ataxia: the MoCA test in English and Hebrew.

Binoy S, Montaser-Kouhsari L, Ponger P, Saban W Front Hum Neurosci. 2024; 17:1325215.

PMID: 38259338 PMC: 10800372. DOI: 10.3389/fnhum.2023.1325215.

A severe neurodegenerative disease with Lewy bodies and a mutation in the glucocerebrosidase gene.

Sipila J, Kytovuori L, Rauramaa T, Rauhamaa H, Kaasinen V, Majamaa K NPJ Parkinsons Dis. 2023; 9(1):53.

PMID: 37019925 PMC: 10076383. DOI: 10.1038/s41531-023-00501-4.

Cognitive and Functional Trajectories in Older Adults With Prediagnostic Parkinson Disease.

Bock M, Vittinghoff E, Bahorik A, Leng Y, Fink H, Yaffe K Neurology. 2022; 100(13):e1386-e1394.

PMID: 36581466 PMC: 10065215. DOI: 10.1212/WNL.0000000000206762.

References

Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca M, Wong K . Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?. Mol Genet Metab. 2003; 79(2):104-9. DOI: 10.1016/s1096-7192(03)00071-4. View

Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, AGHAI E . Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 1996; 89(9):691-4. DOI: 10.1093/qjmed/89.9.691. View

Alcalay R, Mirelman A, Saunders-Pullman R, Tang M, Mejia Santana H, Raymond D . Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord. 2013; 28(14):1966-71. PMC: 3859844. DOI: 10.1002/mds.25647. View

Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F . Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology. 2012; 78(6):417-20. DOI: 10.1212/WNL.0b013e318245f476. View

Nalls M, Pankratz N, Lill C, Do C, Hernandez D, Saad M . Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014; 46(9):989-93. PMC: 4146673. DOI: 10.1038/ng.3043. View

da Silva C, de M Abreu G, Cabello Acero P, Junior M, Pereira J, de A Ramos S . Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease. J Neurol Sci. 2017; 381:160-164. DOI: 10.1016/j.jns.2017.08.3249. View

Clark L, Ross B, Wang Y, Mejia-Santana H, Harris J, Louis E . Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology. 2007; 69(12):1270-7. PMC: 3624967. DOI: 10.1212/01.wnl.0000276989.17578.02. View

Jones A, Tilley M, Gutteridge A, Hyde C, Nagle M, Ziemek D . GWAS of self-reported mosquito bite size, itch intensity and attractiveness to mosquitoes implicates immune-related predisposition loci. Hum Mol Genet. 2017; 26(7):1391-1406. PMC: 5390679. DOI: 10.1093/hmg/ddx036. View

Eriksson N, Macpherson J, Tung J, Hon L, Naughton B, Saxonov S . Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet. 2010; 6(6):e1000993. PMC: 2891811. DOI: 10.1371/journal.pgen.1000993. View

10.

Gan-Or Z, Amshalom I, Kilarski L, Bar-Shira A, Gana-Weisz M, Mirelman A . Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology. 2015; 84(9):880-7. PMC: 4351661. DOI: 10.1212/WNL.0000000000001315. View

11.

Eriksson N, Tung J, Kiefer A, Hinds D, Francke U, Mountain J . Novel associations for hypothyroidism include known autoimmune risk loci. PLoS One. 2012; 7(4):e34442. PMC: 3321023. DOI: 10.1371/journal.pone.0034442. View

12.

Alcalay R, Mejia-Santana H, Tang M, Rosado L, Verbitsky M, Kisselev S . Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009; 66(12):1517-22. PMC: 2837584. DOI: 10.1001/archneurol.2009.267. View

13.

Mirelman A, Heman T, Yasinovsky K, Thaler A, Gurevich T, Marder K . Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation. Mov Disord. 2013; 28(12):1683-90. DOI: 10.1002/mds.25587. View

14.

Lee A, Wang Y, Alcalay R, Mejia-Santana H, Saunders-Pullman R, Bressman S . Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. Mov Disord. 2017; 32(10):1432-1438. PMC: 5656509. DOI: 10.1002/mds.27059. View

15.

West A, Moore D, Biskup S, Bugayenko A, Smith W, Ross C . Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005; 102(46):16842-7. PMC: 1283829. DOI: 10.1073/pnas.0507360102. View

16.

Alcalay R, Caccappolo E, Mejia-Santana H, Tang M, Rosado L, Orbe Reilly M . Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012; 78(18):1434-40. PMC: 3345785. DOI: 10.1212/WNL.0b013e318253d54b. View

17.

Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff J . Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol. 2011; 69(1):193-7. DOI: 10.1002/ana.22165. View

18.

Chang D, Nalls M, Hallgrimsdottir I, Hunkapiller J, van der Brug M, Cai F . A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. 2017; 49(10):1511-1516. PMC: 5812477. DOI: 10.1038/ng.3955. View

19.

Do C, Tung J, Dorfman E, Kiefer A, Drabant E, Francke U . Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 2011; 7(6):e1002141. PMC: 3121750. DOI: 10.1371/journal.pgen.1002141. View

20.

Gan-Or Z, Leblond C, Mallett V, Orr-Urtreger A, Dion P, Rouleau G . LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. Parkinsonism Relat Disord. 2015; 21(7):778-82. DOI: 10.1016/j.parkreldis.2015.05.002. View